📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Park Medi World Q3 Revenue Up 18% to ₹4,100 Mn; 9M PAT Surges 43% with Strategic Acquisitions
Park Medi World reported a strong Q3 FY26 with revenue growing 17.76% YoY to ₹4,100 million and PAT increasing 15.78% to ₹528 million. The 9-month performance was particularly robust, with PAT surging 42.6% YoY to ₹1,968 million, supported by a 65% occupancy rate and improved operational efficiencies. The company aggressively expanded its footprint by acquiring KP Institute of Medical Sciences in Agra for ₹245 crore and Febris Hospital in Delhi. Management remains committed to a cluster-based expansion model, targeting a total capacity of 5,260 beds by March 2028.
Key Highlights
Q3 FY26 Revenue increased 17.76% YoY to ₹4,100 Mn with EBITDA margins expanding to 24.25%.
9M FY26 PAT grew by 42.60% YoY to ₹1,968 Mn, driven by higher patient volumes and better case mix.
Acquired 360-bed KP Institute of Medical Sciences in Agra for ₹245 crore in an all-cash deal.
Average occupancy ratio improved to 65% in 9M FY26 from 62% in the previous year.
Current bed capacity stands at 3,250 with a clear roadmap to reach 5,260 beds by March 2028.
💼 Action for Investors
The company's strong earnings growth and aggressive inorganic expansion into high-density urban catchments signal a positive growth trajectory. Investors should monitor the successful integration of the newly acquired Agra and Delhi assets to ensure margin stability.
Park Medi World Q3 FY26 Revenue Up 18% YoY; PAT Grows 16% to ₹528 Mn
Park Medi World reported a strong Q3 FY26 with revenue growing 18% YoY to ₹4,100 million and PAT increasing 16% to ₹528 million. The 9-month performance was even more robust, with PAT surging 43% YoY to ₹1,968 million, driven by improved occupancy of 65% and higher ARPOB of ₹27,406. The company is aggressively expanding its footprint, having recently acquired 560 beds through Febris Hospital and KPIMS. Management aims to reach a total capacity of 5,260 beds by March 2028, positioning the firm as a dominant player in North India.
Key Highlights
Q3 FY26 revenue rose 18% YoY to ₹4,100 Mn; EBITDA grew 20% to ₹994 Mn.
9M FY26 PAT surged 43% YoY to ₹1,968 Mn with a net margin of 16%.
Average Revenue Per Occupied Bed (ARPOB) increased 7.4% YoY to ₹27,406 in 9M FY26.
Strategic acquisitions of Febris Hospital (Delhi) and KPIMS (Agra) added 560 beds to the network.
Targeting a total capacity of 5,260 beds by March 2028 from the current 3,250 beds.
💼 Action for Investors
Investors should favor the strong operational metrics and aggressive inorganic expansion strategy. Monitor the integration of newly acquired hospitals and their impact on overall margins in the coming quarters.
Park Medi World Authorizes CFO Rajesh Sharma for SEBI Materiality Disclosures
Park Medi World Limited has officially designated its Chief Financial Officer, Mr. Rajesh Sharma, as the authorized Key Managerial Personnel (KMP) under Regulation 30(5) of SEBI LODR. This authorization empowers the CFO to determine the materiality of events or information and ensure timely disclosures to the stock exchanges. The filing is a standard regulatory requirement for listed companies to maintain transparency. Investors should view this as a routine administrative update ensuring compliance with Indian listing norms.
Key Highlights
Authorization of KMP under Regulation 30(5) of SEBI (LODR) Regulations, 2015
Mr. Rajesh Sharma, Chief Financial Officer, designated for materiality determination
Contact details for disclosures provided as +91 124 696 00 00
Compliance notification sent to both BSE (Scrip Code: 544645) and NSE (Symbol: PARKHOSPS)
💼 Action for Investors
No immediate action is required as this is a routine procedural filing. Investors should maintain focus on the company's operational performance and quarterly earnings.
Park Medi World Q3 PAT at ₹368.8M; Announces ₹3.3B in Strategic Acquisitions
Park Medi World Limited reported its first financial results post-listing, with Q3 FY26 consolidated revenue reaching ₹3,670.96 million and a net profit of ₹368.78 million. The company is aggressively pursuing inorganic growth, announcing acquisitions of K P S Wellness and SVPD Healthcare for ₹2,450 million, and Krishna Super-Speciality Hospital for ₹400 million. For the nine-month period ended December 2025, the group achieved a robust net profit of ₹1,671.67 million. IPO proceeds are being actively deployed, with ₹2,225.90 million already utilized for debt repayment and capital expenditure.
Key Highlights
Consolidated Q3 FY26 revenue stood at ₹3,670.96 million with a PAT of ₹368.78 million.
Announced acquisition of K P S Wellness and SVPD Healthcare for ₹2,450 million expected by Feb 2026.
Acquired Febris Multispeciality Hospital for ₹506.8 million via insolvency resolution process.
Approved acquisition of Mahip Hospital Private Limited (250 beds) for ₹400 million in January 2026.
Utilized ₹1,430.90 million of IPO proceeds for debt repayment to strengthen the balance sheet.
💼 Action for Investors
The company's aggressive M&A strategy and strong nine-month profitability suggest a high-growth trajectory post-IPO. Investors should monitor the successful integration of the newly acquired hospitals and their impact on consolidated margins.
Paradeep Phosphates Credit Rating Upgraded to [ICRA]AA- (Stable) for ₹6,000 Cr Long-term Debt
ICRA Limited has upgraded the credit ratings for Paradeep Phosphates Limited's bank facilities and instruments totaling over ₹17,500 crores. The long-term ratings for ₹6,000 crores in fund-based facilities (Cash Credit and Term Loans) moved from [ICRA]A+ to [ICRA]AA- with a Stable outlook. Short-term ratings for ₹11,200 crores in non-fund based facilities and ₹300 crores in commercial paper were also upgraded to the highest category of [ICRA]A1+. This upgrade reflects improved financial stability and creditworthiness, which could potentially lead to lower borrowing costs for the company.
Key Highlights
Long-term rating for ₹3,000 crore Cash Credit upgraded to [ICRA]AA- from [ICRA]A+
Long-term rating for ₹3,000 crore Term Loan upgraded to [ICRA]AA- with a Stable outlook
Short-term rating for ₹11,200 crore Non-fund based facilities upgraded to [ICRA]A1+
Commercial Paper rating for ₹300 crore upgraded to [ICRA]A1+
Ratings removed from 'Watch with developing implications' status to 'Stable' outlook
💼 Action for Investors
Investors should view this as a positive signal of the company's strengthening balance sheet and reduced credit risk. Monitor the upcoming quarterly results to see if the improved rating translates into lower interest expenses.